Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | post |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | pre |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | pre |